Skip to content

Effect of Unani drugs in Acidity

Efficacy of Sufoof-i-Tabkheer and Arq-i-Badiyan in Dyspepsia- An open labelled single Arm Clinical Study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/04/024500
Enrollment
30
Registered
2020-04-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K318- Other specified diseases of stomach and duodenum

Interventions

Intervention1: Safuf-i-Tabkheer and Arq-i -Badiyan: Safuf-i-Tabkheer 6gm and Arq-i -Badiyan 60ml orally in the morning and Evening after meal for 28 days. Control Intervention1: Not applicable: Not

Sponsors

National Institute of Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Symptoms persist at least for 1 month with moderate to severe symptoms (score > 4 on the 7 point Global overall symptoms (GOS) scale).

Exclusion criteria

Exclusion criteria: 1.Patients age below 18 and above 50 year 2.Patients with severe systemic and metabolic diseases 3.History of angina pectoris 4.Pregnant and lactating women 5.Patients with alarming symptoms (unintentional weight loss, recurrent vomiting, dysphasia, hematemesis, Malena, fever, jaundice, anemia. 6.History of any serious gastrointestinal disease including peptic ulcer, malignancy, dysmotility. 7.Previous endoscopic diagnosis of erosive gastro-esophagitis or Barrett esophagus. 8.Gastrointestinal surgery within 30 days. 9.Hemoglobin 120 IU/L, Serum creatinine >1.5 mg/dl, Occult blood in stool. 10.Treatment history of NSAIDs, H2 receptors blockers, PPI, Prokinetic drugs, sucralfate or other ulcer healing agents within 15 days prior to enrolment. 11.Concomitant use of psychotropic drugs. 12.History of alcohol consumption

Design outcomes

Primary

MeasureTime frame
GOS (Global over all symptoms) scaleTimepoint: 0th , 7th, 14th, 21st and 28th Day

Secondary

MeasureTime frame
1.Changes in the clinical global impression (CGI) scale score22 2.Unani Medicine Symptom Score5 (SS) Timepoint: 0th , 7th, 14th, 21st and 28th Day

Countries

India

Contacts

Public ContactAbdul Mobeen

National Institute of Unani Medicine

dr.mobeen@rediffmail.com8123143721

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026